Search clinical trials for: influenza vaccines

Total 5880 results

Sanofi

Completed

Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years

Influenza | Flu

China
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine

Influenza

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India

Influenza

India
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.

Influenza

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Taiwan
Jiangsu Province Centers for Disease Control and...

Completed

Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine

COVID-19

China
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years

Influenza | Flu, Human

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (QHD04)

Influenza

United States, Canada
Sanofi Pasteur, a Sanofi Company
Sanofi K.K.

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years

Influenza

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations (GRC90)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

Influenza

United States, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

Influenza | Flu

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)

Influenza

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years

Influenza

Korea, Republic of
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA

Influenza

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Yellow Fever | Dengue | Dengue Hemorrhagic Fever

Peru, Colombia
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Singapore
Canadian Immunization Research Network
GlaxoSmithKline; Dalhousie University; MCM Vaccines B.V.; Canadian Center for Vaccinology

Completed

Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction

Healthy

Canada
FluGen Inc

Completed

Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Influenza A

United States
National Institute of Allergy and Infectious Diseases...

Completed

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

Influenza

United States
Peking University
Shandong University; Fudan University; Centers for Disease Control and Prevention...

Completed

Financing Strategies of Influenza Vaccination in China

Influenza, Human | Health Knowledge, Attitudes, Practice | Influenza Vaccines | Cost of Illness | Immunization Programs

China
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; National Heart, Lung, and Blood... and other collaborators

Completed

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)

Myocardial Infarction | Heart Failure

United States, Canada, Puerto Rico
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old

Influenza

Russian Federation
University of Rochester
National Institutes of Health (NIH)

Completed

Comparison of Three Licensed Influenza Vaccines

Influenza

United States
University of California, Los Angeles
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Patient Portal - Flu Reminder Recall

Respiratory Tract Infections | Influenza | Vaccines

United States
GlaxoSmithKline

Completed

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

Influenza | Influenza Vaccines

United States, Thailand, Canada
National Institute of Allergy and Infectious Diseases...

Withdrawn

Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals

HIV Infections
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents

HIV Infections | Influenza

United States, Puerto Rico
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

Glioma | Astrocytoma | Oligodendroglioma

United States
National Institute of Allergy and Infectious Diseases...

Completed

H3N2 M2SR in Pediatric Population

Influenza | Influenza Immunisation

United States
Richard Zimmerman MD
Centers for Disease Control and Prevention

Completed

Immunologic Response to FluMist vs. Flucelvax

Immune Response | Influenza, Human

United States
MedImmune LLC

Completed

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Influenza Vaccine

United States
Ole Frobert, MD, PhD
Uppsala University; Sanofi Pasteur, a Sanofi Company; Swedish Heart Lung Foundation and other collaborators

Completed

Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis (IAMI)

Myocardial Infarction | Heart Failure | Stroke | Influenza, Human | Influenza Vaccines

Denmark, United Kingdom, Sweden, Australia, Bangladesh, Czechia, Latvia, Norway
University of Rochester

Completed

Influenza Immunity in Children

Influenza

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

Healthy

United States
Ross University School of Veterinary Medicine
Serum Institute of India Pvt. Ltd.

Completed

Non-specific Effects of Rabies Vaccine

Diarrhea | Fever | Influenza-like Illness | Upper Respiratory Disease

Saint Kitts and Nevis
Bayer
CureVac

Withdrawn

COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older (CV-NCOV-011)

Coronavirus Disease 2019 (COVID-19) | SARS-CoV-2 Infection
National Institute of Allergy and Infectious Diseases...

Completed

2017 A/H7N9 IIV Revaccination

Influenza Immunisation | Avian Influenza

United States
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial With Influenza A/H1N1 Vaccines

Influenza

China
Sinovac Research and Development Co., Ltd.

Completed

Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine

COVID-19 | Influenza

China
Donald T. Weed, MD, FACS

Completed

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States
University of California, Los Angeles
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pediatric Second Influenza Dose Portal Reminder Recall

Respiratory Tract Infections | Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Age and Response to Flu Vaccines

Influenza | Influenza Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Influenza Immunisation | Avian Influenza

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Influenza, Human

United States, Belgium
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany

3

Subscribe